|By JCN Newswire||
|July 30, 2014 10:47 PM EDT||
Tokyo, July 31, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate ("lenvatinib") in the treatment of radioiodine-refractory differentiated thyroid cancer.
The EMA's accelerated review procedure is granted for new medicines that are expected to be of major public health interest, particularly from the viewpoint of therapeutic innovation. Currently, Eisai is planning to submit applications for marketing authorization in Europe and the U.S. in the second quarter of fiscal 2014. In addition, the first application for marketing authorization of lenvatinib in the world was submitted in Japan on June 2014.
Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor (PDGF) receptor PDGFRα, KIT and RET that are involved in tumor proliferation. This potentially makes lenvatinib a first-in-class treatment, especially given that it simultaneously inhibits the kinase activities of FGFR as well as VEGFR. It was granted Orphan Drug Designation for thyroid cancer by the health authorities in Japan, Europe and the U.S. In Europe alone, over 50,000 cases of thyroid cancer were diagnosed in 2012. Although treatment is possible for most types of thyroid cancer, there remains an unmet need for treatment options once the disease has progressed.
Eisai is committed to exploring the potential clinical benefits of lenvatinib in order to further contribute to patients with cancer and their families.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Eisai Co., Ltd. +81-(0)3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Jul. 29, 2016 06:15 PM EDT Reads: 947
Jul. 29, 2016 06:00 PM EDT Reads: 913
Jul. 29, 2016 05:15 PM EDT Reads: 368
Jul. 29, 2016 05:15 PM EDT Reads: 974
Jul. 29, 2016 04:45 PM EDT Reads: 1,240
Jul. 29, 2016 04:15 PM EDT Reads: 387
Jul. 29, 2016 04:15 PM EDT Reads: 1,079
Jul. 29, 2016 04:15 PM EDT Reads: 419
Jul. 29, 2016 03:15 PM EDT Reads: 655
Jul. 29, 2016 03:00 PM EDT Reads: 443
Jul. 29, 2016 02:15 PM EDT Reads: 377
Jul. 29, 2016 02:00 PM EDT Reads: 1,203
Jul. 29, 2016 01:00 PM EDT Reads: 767
Jul. 29, 2016 01:00 PM EDT Reads: 729
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Jul. 29, 2016 01:00 PM EDT Reads: 1,195